Valneva SE (VALN) released encouraging Phase 2 data Wednesday for VLA15, its Lyme disease vaccine candidate developed in partnership with Pfizer Inc. (PFE). The results demonstrate sustained immunity and a reassuring safety profile six months after a third booster dose, reinforcing the viability of annual pre-season vaccination.
Lyme disease, caused by bacteria transmitted through infected tick bites, typically announces itself with a distinctive "bull's-eye" rash and flu-like symptoms including fever, headache, and fatigue. It's more common than you might think: the Centers for Disease Control and Prevention estimates roughly 476,000 Americans are diagnosed and treated for Lyme disease each year, while Europe reports 132,000 annual cases.
What the Data Shows
The Phase 2 study, designated VLA15-221, tracked participants who received a third booster dose at month 42 and measured their immune response at month 48. The vaccine triggered what researchers call a "strong anamnestic immune response"—essentially, the immune system's ability to rapidly remember and respond to a threat it's seen before.
Here's where it gets interesting: the study compared two different primary vaccination schedules. The three-dose schedule (given at months 0, 2, and 6) consistently delivered higher antibody levels than the two-dose alternative. Six months after the booster, antibody levels had declined from their initial spike but remained substantially above baseline across all study groups.
The immune response varied by age, with kids aged 5 to 11 showing the strongest results. In this age group, geometric mean fold rise (GMFR) levels ranged from 15.5-fold for Serotype 1 to an impressive 28.5-fold for Serotype 2. Across all age groups using the three-dose schedule, GMFRs ranged from 9.5-fold for ST1 to 15.6-fold for ST2 compared to baseline.
These findings validate the decision to use a three-dose primary vaccination schedule followed by yearly boosters—an approach already baked into the Phase 3 clinical trial protocols.
The Pfizer Partnership and Regulatory Timeline
Pfizer and Valneva joined forces on VLA15 back in April 2020. Now, assuming the Phase 3 data comes back positive, Pfizer aims to submit a Biologics License Application to the U.S. Food and Drug Administration and a Marketing Authorization Application to the European Medicines Agency in 2026.
The safety profile remains encouraging. Six months after the third booster dose, the vaccine's safety and tolerability mirrored what researchers observed after previous booster doses—no new concerns emerged.
Operational Consolidation
Beyond the clinical news, Valneva also announced Wednesday a strategic reorganization of its French operations. The company plans to concentrate its activities at its Lyon location while closing the Nantes site, which currently handles operational functions and certain pre-clinical R&D activities. Management framed this as an optimization move designed to improve operational effectiveness and position the company for long-term success.
Investors seemed to like the combination of positive vaccine data and operational streamlining. Valneva shares climbed 7.65% to $9.19 following the announcements Wednesday.
